Search

The present work is aimed to study the interactions between cefpirome and hypoglycemic agents (gliquidone, metformin, and pioglitazone) by chromatographic and spectroscopic techniques. In the first case, reversed-phase high-performance liquid chromatographic methods have been developed, validated for the simultaneous determination of cefpirome with hypoglycemic agents, and was applied for interaction studies. These interactions were carried out in simulated gastric juice (pH1), buffers of pH 4, 7.4, and 9 at 37 °C for 3 h. In the second case, cefpirome–hypoglycemic agents complexes were synthesized and elucidated on the basis of FT-IR, 1H-NMR, and 13C-NMR studies.

In present paper, we describe in vitro drug interactions of antidiabetic agents; gliquidone and pioglitazone hydrochloride with an antihypertensive, losartan potassium. Co-administration of antihypertensive and antidiabetic drugs is most common, as both of these ailments are synergistic to each other and often occur together. These studies were carried out in different pH environments simulating human body compartments and using UV spectrophotometer and HPLC. Antidiabetic agents and losartan were found to inhibit or enhance each other’s availability, which may affect their therapeutic efficacy. These results were further verified by IR and NMR spectroscopic studies and computational molecular modeling.

Controlling blood sugar levels is crucial for diabetic patients and is managed through administration of drugs such as gliquidone. Coadministration of antidiabetic drugs with H1-receptor antagonists is common but is also a source of concern due to potential coadministered drug interaction, especially in patients prone to allergic disorders. In this work, we describe in vitro drug interactions of gliquidone with commonly coadministered H1-receptor antagonists (fexofenadine hydrochloride, cetirizine dihydrochloride, and levocetirizine dihydrochloride). These studies were performed at 37°C in different pH environments simulating human body compartments using UV spectrophotometry and high performance liquid chromatography (HPLC). It was observed that the percentage availability values of gliquidone and H1-receptor antagonists were not affected in the presence of each other. No significant difference between gliquidone and H1-receptor antagonists and no remarkable changes in availability values were observed when these interactions were studied using UV–visible and HPLC techniques. This study thus supports the safe coadministration of gliquidone and H1-receptor blockers as an effective diabetic health management regimen.